Ying GS, Huang J, Maguire MG, Jaffe GJ, Grunwald JE, Toth C, et al. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology. 2013;120:122–9.

Article  PubMed  Google Scholar 

Maguire MG, Martin DF, Ying GS, Jaffe GJ, Daniel E, Grunwald JE, et al. Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016;123:1751–61.

Article  PubMed  Google Scholar 

Hashimoto Y, Okada A, Matsui H, Yasunaga H, Aihara M, Obata R. Recent trends in anti-vascular endothelial growth factor intravitreal injections: a large claims database study in Japan. Jpn J Ophthalmol. 2023;67:109–18.

Article  CAS  PubMed  Google Scholar 

Sawada T, Yasukawa T, Imaizumi H, Matsubara H, Kimura K, Terasaki H, et al. Subtype prevalence and baseline visual acuity by age in Japanese patients with neovascular age-related macular degeneration. Jpn J Ophthalmol. 2023;67:149–55.

Article  CAS  PubMed  Google Scholar 

Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–31.

Article  CAS  PubMed  Google Scholar 

Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus Verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432–44.

Article  CAS  PubMed  Google Scholar 

Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120:2292–9.

Article  PubMed  Google Scholar 

Spaide R. Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol. 2007;143:679–80.

Article  PubMed  Google Scholar 

Chin-Yee D, Eck T, Fowler S, Hardi A, Apte RS. A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration. Br J Ophthalmol. 2016;100:914–7.

Article  PubMed  Google Scholar 

Oubraham H, Cohen SY, Samimi S, Marotte D, Bouzaher I, Bonicel P, et al. Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration. Retina. 2011;31:26–30.

Article  CAS  PubMed  Google Scholar 

Kuroda Y, Yamashiro K, Miyake M, Yoshikawa M, Nakanishi H, Oishi A, et al. Factors associated with recurrence of age-related macular degeneration after anti-vascular endothelial growth factor treatment: a retrospective cohort study. Ophthalmology. 2015;122:2303–10.

Article  PubMed  Google Scholar 

Freund KB, Zweifel SA, Engelbert M. Do we need a new classification for choroidal neovascularization in age-related macular degeneration? Retina. 2010;30:1333–49.

Article  PubMed  Google Scholar 

Coscas G, Lupidi M, Coscas F, Français C, Cagini C, Souied EH. Optical coherence tomography angiography during follow-up: qualitative and quantitative analysis of mixed type I and II choroidal neovascularization after vascular endothelial growth factor trap therapy. Ophthalmic Res. 2015;54:57–63.

Article  CAS  PubMed  Google Scholar 

Matsumoto H, Morimoto M, Mimura K, Ito A, Akiyama H. Treat-and-extend regimen with aflibercept for neovascular age-related macular degeneration: efficacy and macular atrophy development. Ophthalmol Retina. 2018;2:462–8.

Article  PubMed  Google Scholar 

Lee JY, Chung H, Kim HC. Changes in fundus autofluorescence after anti-vascular endothelial growth factor according to the type of choroidal neovascularization in age-related macular degeneration. Korean J Ophthalmol. 2016;30:17–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Steinle NC, Du W, Gibson A, Saroj N. Outcomes by baseline choroidal neovascularization features in age-related macular degeneration: a post hoc analysis of the VIEW studies. Ophthalmol Retina. 2021;5:141–50.

Article  PubMed  Google Scholar 

Suzuki M, Gomi F, Sawa M, Tsujikawa M, Sakaguchi H. Bevacizumab treatment for choroidal neovascularization due to age-related macular degeneration in Japanese patients. Jpn J Ophthalmol. 2010;54:124–8.

Article  CAS  PubMed  Google Scholar 

Wada I, Oshima Y, Shiose S, Kano K, Nakao S, Kaizu Y, et al. Five-year treatment outcomes following intravitreal ranibizumab injections for neovascular age-related macular degeneration in Japanese patients. Graefes Arch Clin Exp Ophthalmol. 2019;257:1411–8.

Article  CAS  PubMed  Google Scholar 

Bloch SB. Implementation studies of ranibizumab for neovascular age-related macular degeneration. Acta Ophthalmol. 2013;91 Thesis7:1–22.

Article  PubMed  Google Scholar 

Munk MR, Ceklic L, Ebneter A, Huf W, Wolf S, Zinkernagel MS. Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration. Acta Ophthalmol. 2016;94:e757–64.

Article  CAS  PubMed  Google Scholar 

Ohji M, Okada AA, Sasaki K, Moon SC, Machewitz T, Takahashi K. Relationship between retinal fluid and visual acuity in patients with exudative age-related macular degeneration treated with intravitreal aflibercept using a treat-and-extend regimen: subgroup and post-hoc analyses from the ALTAIR study. Graefes Arch Clin Exp Ophthalmol. 2021;259:3637–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wakazono T, Yamashiro K, Oishi A, Ooto S, Tamura H, Akagi-Kurashige Y, et al. Recurrence of choroidal neovascularization lesion activity after aflibercept treatment for age-related macular degeneration. Retina. 2017;37:2062–8.

Article  PubMed  Google Scholar 

Hirata Y, Oishi A, Maekawa Y, Tsuiki E, Machida A, Kurihara J, et al. Recurrence of neovascular age-related macular degeneration after cessation of treat and extend regimen. Sci Rep. 2022;12:14768.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ohnaka M, Nagai Y, Sho K, Miki K, Kimura M, Chihara T, et al. A modified treat-and-extend regimen of aflibercept for treatment-naïve patients with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2017;255:657–64.

Article  CAS  PubMed  Google Scholar 

Kim JH, Kim JW, Kim CG. Five-year reactivation after ranibizumab or aflibercept treatment for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. J Ocul Pharmacol Ther. 2021;37:525–33.

Article  CAS  PubMed  Google Scholar 

Cho HJ, Jeon YJ, Yoon W, Yoon J, Kim J, Kim JW. Neovascular age-related macular degeneration without exudative recurrence over 24 months after initial remission. Sci Rep. 2022;12:15662.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oishi A, Mandai M, Nishida A, Hata M, Matsuki T, Kurimoto Y. Remission and dropout rate of anti-VEGF therapy for age-related macular degeneration. Eur J Ophthalmol. 2011;21:777–82.

Article  PubMed  Google Scholar 

Gomi F, Kawasaki R, Ogura Y, Iwasaki K, Takeshima T, Yamabe M, et al. Patterns of anti-vascular endothelial growth factor treatment for chorioretinal vascular diseases: analysis of a nationwide claims database in Japan. Ann Clin Epidemiol. 2024;6:42–50.

Article  PubMed  PubMed Central  Google Scholar